iCAD Announced Health Canada Has Issued A Device License For Profound Risk Version 2.0, The Latest Version Of iCAD's Personalized 1-2 Year Breast Cancer Risk Assessment Solution
Portfolio Pulse from Benzinga Newsdesk
iCAD has announced that Health Canada has issued a device license for Profound Risk Version 2.0, the latest version of iCAD's personalized 1-2 year breast cancer risk assessment solution.
August 16, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
iCAD's latest version of its personalized breast cancer risk assessment solution, Profound Risk Version 2.0, has received a device license from Health Canada. This could potentially increase the company's market reach and revenues.
The issuance of a device license by Health Canada for iCAD's Profound Risk Version 2.0 signifies regulatory approval for the product in Canada. This could potentially increase the product's market reach, leading to increased sales and revenues for iCAD. Therefore, this news is likely to have a positive impact on iCAD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100